Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab +/- Tislelizumab in Advanced Solid Tumors (AdvanTIG-105)
NCT04047862Phase 1Completed
- Sponsor
- BeiGene
- Start
- Aug 2019
- Primary completion
- Aug 2024
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
Phase 1, open-label trial of ociperlimab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC) and 4 more (17 arms), sponsored by BeiGene. Primary endpoints: Treatment Emergent Adverse Events, Dose Limiting Toxicities at 28 days and 3 more. Started Aug 2019; status: completed.
02
Drugs
ociperlimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04047862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047862.